HomeCompareBXS vs ABBV

BXS vs ABBV: Dividend Comparison 2026

BXS yields 73.72% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BXS wins by $2955258703469.90M in total portfolio value
10 years
BXS
BXS
● Live price
73.72%
Share price
$28.76
Annual div
$21.20
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2955258703470.01M
Annual income
$2,947,577,713,741,642,000.00
Full BXS calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BXS vs ABBV

📍 BXS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBXSABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BXS + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BXS pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BXS
Annual income on $10K today (after 15% tax)
$6,266.21/yr
After 10yr DRIP, annual income (after tax)
$2,505,441,056,680,396,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, BXS beats the other by $2,505,441,056,680,375,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BXS + ABBV for your $10,000?

BXS: 50%ABBV: 50%
100% ABBV50/50100% BXS
Portfolio after 10yr
$1477629351735.05M
Annual income
$1,473,788,856,870,833,400.00/yr
Blended yield
99.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BXS
Analyst Ratings
7
Buy
13
Hold
Consensus: Hold
Altman Z
1.0
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BXS buys
0
ABBV buys
0
No recent congressional trades found for BXS or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBXSABBV
Forward yield73.72%3.06%
Annual dividend / share$21.20$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$2955258703470.01M$102.3K
Annual income after 10y$2,947,577,713,741,642,000.00$24,771.77
Total dividends collected$2954753912979.87M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: BXS vs ABBV ($10,000, DRIP)

YearBXS PortfolioBXS Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$25,444$14,744.02$11,550$430.00+$13.9KBXS
2$97,346$70,120.96$13,472$627.96+$83.9KBXS
3$605,609$501,448.92$15,906$926.08+$589.7KBXS
4$6,479,055$5,831,053.34$19,071$1,382.55+$6.46MBXS
5$123,536,320$116,603,730.93$23,302$2,095.81+$123.51MBXS
6$4,287,859,532$4,155,675,669.98$29,150$3,237.93+$4287.83MBXS
7$274,196,617,197$269,608,607,497.71$37,536$5,121.41+$274196.58MBXS
8$32,519,027,631,835$32,225,637,251,433.38$50,079$8,338.38+$32519027.58MBXS
9$7,178,495,073,237,400$7,143,699,713,671,337.00$69,753$14,065.80+$7178495073.17MBXS
10$2,955,258,703,470,006,300$2,947,577,713,741,642,000.00$102,337$24,771.77+$2955258703469.90MBXS

BXS vs ABBV: Complete Analysis 2026

BXSStock

BancorpSouth Bank provides commercial banking and financial services to individuals and small-to-medium size businesses. The company operates through Banking Services Group, Mortgage, Insurance Agencies, Wealth Management, and General Corporate and Other segments. It offers various deposit products, including interest and noninterest bearing demand deposits, and saving and other time deposits. The company also provides commercial loans, including term loans, lines of credit, equipment and receivable financing, and agricultural loans; a range of short-to-medium term secured and unsecured commercial loans to businesses for working capital, business expansion, and the purchase of equipment and machinery; and construction loans to real estate developers for the acquisition, development, and construction of residential subdivisions. In addition, it offers fixed and adjustable rate residential mortgage loans secured by owner-occupied property; residential construction loans; second mortgage loans; and home equity lines of credit, as well as non-residential consumer loans that consist of automobile, recreation vehicle, boat, personal, and deposit account secured loans, as well as issues credit cards. Further, the company operates as an agent for the sale of commercial lines of insurance; and offers a line of property and casualty, life, health, and employee benefits products and services. Additionally, it provides credit related products, trust and investment management, asset management, retirement and savings solutions, and estate planning and annuity products. It operates in Alabama, Arkansas, Florida, Louisiana, Mississippi, Missouri, Tennessee, Texas, and Illinois. The company was formerly known as BancorpSouth, Inc. and changed its name to BancorpSouth Bank in October 2017. BancorpSouth Bank was founded in 1876 and is headquartered in Tupelo, Mississippi.

Full BXS Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BXS vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BXS vs SCHDBXS vs JEPIBXS vs OBXS vs KOBXS vs MAINBXS vs JNJBXS vs MRKBXS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.